13158 Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Notices

3. Survey Component of the CDC’s

Prevention Marketing Initiative Local

Demonstration Site Project Evaluation

—NEW— The Centers for Disease

Control and Prevention, National Center

for HIV, STD, and TB Prevention,

Division of HIV/AIDS Prevention,

Behavioral Intervention Research

Branch is planning to conduct a crosssectional tracking study as part of the

evaluation of a five-city HIV prevention

demonstration program. The program

involves the integration of social

marketing strategies and community

participation in an effort to develop and

implement HIV prevention activities.

Charged with developing programs for

those 25 years of age and younger,

community groups in the local

demonstration sites chose to segment

the target audience even further, and to

mount a variety of types of

interventions. Decisions about

segmentation and the nature of local

interventions were based on formative

research conducted in each community.

It is hoped that this demonstration

project will result in reductions in HIV

risk behavior among members of the

target audiences, as well as in enhanced

collaboration among individuals and

organizations in the participating

communities.

As part of the evaluation of the

effectiveness of the interventions,

questionnaire data will be collected in

three of the demonstration

communities. These data will be

collected at four time points over a two

year period after prevention activities

and message campaigns are launched.

Baseline survey data have been

collected recently under OMB No.0920–

0343 (Evaluation of the National AIDS

information and Education Program

Activities). The total annual burden

hours are 4,260.

Respondents Number of

respondents

Number of

responses/

respondent

Average burden/response

(in hrs.)

Total burden

(in hrs.)

Eligibility Screening ........................................................................................................ 157,680 1 0.01667 2,628

Consent .......................................................................................................................... 5,768 1 0.05 289

Young People under 25 years of age in targeted prevention program communities .... 3,504 1 0.3833 1,343

Dated: March 13, 1997.

Wilma G. Johnson,

Acting Associate Director for Policy Planning

And Evaluation, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–6887 Filed 3–18–97; 8:45 am]

BILLING CODE 4163–18–P

Meeting Announcement

The National Center for

Environmental Health (NCEH) of the

Centers for Disease Control and

Prevention (CDC) announces the

following meeting:

Name: Preventing Birth Defects Due to

Thalidomide Exposure.

Time and date: 8 a.m.-5 p.m., March 26,

1997.

Place: Sheraton Colony Square Hotel, 188

14th Street, NE, Atlanta, Georgia 30361.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 75 people.

Registration is not required.

Purpose: The meeting will enable academic

and public health professionals to discuss

strategies to prevent birth defects due to

exposure to thalidomide and other human

teratogens. Thalidomide, a potent human

teratogen, is now available as an

investigational drug in the USA. Although

the drug is currently being considered for

approval only for the treatment of leprosy, its

potential applications appear to be

numerous. This meeting will bring together

leaders from the fields of birth defects

research, clinical practice, bioethics, and

public health to review existing strategies for

limiting intrauterine exposure to human

teratogens, and to discuss and provide

individual input on new approaches for

preventing birth defects due to future

teratogens such as thalidomide.

Matters to be discussed: Agenda items will

include presentations on the following

topics: (1) Assessment of the Accutane

Pregnancy Prevention Program, (2) use and

limitations of drug registries, (3)

contraception efficacy, (4) ethical issues on

teratogen exposure, and (5) measures to

assure appropriate use of pharmaceuticals.

Group discussions on strategies for health

care provider education, patient education,

and appropriate use of pharmaceuticals will

follow the presentations. Written materials

may be submitted to CDC until March 21,

1997, for distribution to meeting participants.

Agenda items are subject to change as

priorities dictate.

FOR FURTHER INFORMATION

CONTACT: Dwight Jones, Division of Birth

Defects and Developmental Disabilities,

NCEH, CDC, 4770 Buford Highway, NE, M/

S F–45, Atlanta, Georgia 30341–3724,

telephone 770/488–7160, Fax 770/488–7197.

Dated: March 13, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–7017 Filed 3–18–97; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

Request for Nominations for a

Nonvoting Representative of Industry

Interests on a Public Advisory

Committee

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is requesting

nominations for a nonvoting industry

representative to serve on the

Nonprescription Drugs Advisory

Committee in the Center for Drug

Evaluation and Research. This vacancy

will occur on June 1, 1997.

FDA has a special interest in ensuring

that women, minority groups, and

individuals with disabilities are

adequately represented on advisory

committees and, therefore, the agency

encourages nominations of

appropriately qualified candidates from

these groups.

DATES: Nominations should be received

by April 18, 1997.

ADDRESSES: All nominations and

curricula vitae for the industry

representative should be sent to Andrea

G. Neal (address below).

FOR FURTHER INFORMATION CONTACT:

Andrea G. Neal, Center for Drug

Evaluation and Research (HFD–21),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–443–5455, or FAX 301–443–0699.

SUPPLEMENTARY INFORMATION: FDA is

requesting that any industry

organization interested in participating

in the selection of an appropriate

nonvoting member to represent industry

interests should send a letter to the

contact person (address above). After 30

days, a letter will be sent to each

organization that has made a

nomination, and to those organizations

indicating an interest in participating in

the selection process, together with a

complete list of all such organizations

and the nominees. This letter will state

that it is the responsibility of each

organization indicating an interest in

participating in the selection process to

consult with the others in selecting a
Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Notices 13159

single member representing industry

interests for the committee within 60

days after receipt of the letter. If no

individual is selected within 60 days,

the agency will select the nonvoting

member representing industry interests.

The term of office is 4 years.

Dated: March 13,1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–6848 Filed 3–18–97; 8:45 am]

BILLING CODE 4160–01–F

[Docket Nos. 96N–0421 and 94P–0453]

Agency Information Collection

Activities; Announcement of OMB

Approval

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled,

‘‘Notification of Nutrient Content

Claims for Fat or Fatty Acids Based on

Digestibility Factors’’, has been

approved by the Office of Management

and Budget (OMB) under the Paperwork

Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Margaret R. Wolff, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, rm. 16B–19, Rockville,

MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the

Federal Register of December 20, 1996

(61 FR 67243 at 67256), the agency

announced that the proposed

information collection had been

submitted to OMB for review and

clearance under section 3507 of the

Paperwork Reduction Act of 1995 (44

U.S.C. 3507). OMB has approved the

information collection and has assigned

OMB control number 0910–0334. The

approval expires on February 28, 2000.

An agency may not conduct or sponsor,

and a person is not required to respond

to, a collection of information unless it

displays a currently valid OMB control

number.

Dated: March 12, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–6877 Filed 3–18–97; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Institute of Mental Health;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings of the National Institute of

Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: March 27, 1997.

Time: 2 p.m.

Place: Parklawn, Room 9C–26, 5600

Fishers Lane, Rockville, MD 20857.

Contact Person: Jean G. Noronha,

Parklawn, Room 9C–26, 5600 Fishers Lane,

Rockville, MD 20857; Telephone: 301, 443–

6470.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: April 9, 1997.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Jean G. Noronha,

Parklawn, Room 9C–26, 5600 Fishers Lane,

Rockville, MD 20857; Telephone: 301, 443–

6470.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than

fifteen days prior to the meetings due to the

urgent need to meet timing limitations

imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance

Program Numbers 93.242, 93.281, 93.282.)

Dated: March 14, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6943 Filed 3–18–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Neurological

Disorders and Stroke, Division of

Extramural Activities; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Name of Committee: National Institute of

Neurological Disorders and Stroke Special

Emphasis Panel.

Date: April 18, 1997.

Time: 8:00 A.M.

Place: Holiday Inn Bethesda, 8120

Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Dr. Howard Weinstein,

Scientific Review Administrator, National

Institutes of Health, 7550 Wisconsin Avenue,

Room 9C10, Bethesda, MD s0892, (301) 496–

9223.

Purpose/Agenda: To review and evaluate a

grant application.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.853, Clinical Research

Related to Neurological Disorders; No.

93.854, Biological Basis Research in the

Neurosciences).

Dated: March 12, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6858 Filed 3–18–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Dental Research;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Dental Research

Special Emphasis Panel (SEP) meeting:

Name of SEP: National Institute of Dental

Research Special Emphasis Panel-Contract

Review-Amalgum (97–C).

Dates: March 17, 1997.

Time: 3:00 p.m.

Place: National Institutes of Health, 4500

Center Drive, Natcher Building, Room 4AN–

44F, Bethesda, MD 20892, (Teleconference).

Contact person: Dr. George Hausch, Chief,

Office of Review, 4500 Center Drive, Natcher

Building, Room 4AN–44F, Bethesda, MD

20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review

contract proposals. This notice is being

published less than fifteen days prior to the

meeting due to the urgent need to meet

timing limitations imposed by the review and

funding cycle.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.121, Oral Diseases and

Disorders Research)